市场调查报告书
商品编码
1454083
到 2030 年红曲米市场预测:按产品类型、分销管道、应用、最终用户和地区进行的全球分析Red Yeast Rice Market Forecasts to 2030 - Global Analysis By Product Type (Powder, Extracts, Fermented Products, Capsule & Tablet and Other Product Types), Distribution Channel, Application, End User and By Geography |
根据Stratistics MRC预测,2023年全球红曲米市场规模将达11亿美元,预计2030年将达到24亿美元,预测期内复合年增长率为12.4%。
红曲米(RYR)是一种传统的中国菜餚和药物,由红曲菌发酵米製成。莫纳可林 K 含有一种天然化合物莫纳可林,与降胆固醇药物洛伐他汀相同。几个世纪以来,RYR 一直被用于传统中医以促进心血管健康。其活性化合物被认为可以抑制胆固醇合成并降低低密度脂蛋白(「坏」)胆固醇水平。有些人使用 RYR 作为控制胆固醇水平的天然替代品。
人们对天然降胆固醇药物的认识不断增强
红曲米越来越受欢迎。人们越来越意识到传统降胆固醇药物的副作用,促使人们转向自然疗法。消费者正在积极寻找像红曲米产品可以提供一种自然的方法来控制胆固醇而不损害整体健康。因此,随着人们意识到红曲米在传统医学中的历史用途与采用天然植物性健康解决方案的更广泛趋势之间的一致性,对红曲米的需求激增。
安全问题和潜在的副作用
对红曲米安全性的担忧给市场蒙上了阴影。与严格监管的处方药不同,红曲米会导致肌肉疼痛、消化器官系统问题,并与其他药物产生交互作用。这些潜在的副作用给消费者和医疗保健专业人员带来了危险信号。担心意外后果的消费者可能会选择成熟的药物。由于缺乏长期资料以及与目前药物的潜在交互作用,优先考虑患者安全的医生也可能会犹豫是否推荐红曲米。
心血管疾病盛行率增加
全球对心血管健康的关注日益增加,对有助于控制胆固醇(心血管健康的重要因素)的天然解决方案的需求也随之增加。红曲米含有莫纳可林等可降低胆固醇水平的化合物,已被认为是预防心臟相关问题的潜在预防措施。越来越多的心血管疾病患者促使他们寻求积极主动的方法来管理他们的心臟健康,而红曲米补充品的采用正在促进市场的成长。
与现有降胆固醇药物的竞争
现有降胆固醇药物的主导地位对红曲米市场构成了主要障碍。这些处方药拥有悠久的疗效证明、广泛的临床研究和医生的信任。这使得这些药物成为许多医疗保健提供者的选择,从而阻止红曲米被纳入主流胆固醇管理。此外,现有药物可能包含在保险范围内,与红曲米的自付费用相比,对于某些患者来说,它们成为更具成本效益的选择。
COVID-19 的影响
COVID-19大流行对红曲米市场产生了两个重要影响。首先,人们的注意力已经转向眼前的健康问题。人们优先考虑 COVID-19 的治疗和预防,而将高胆固醇等慢性健康问题放在次要位置。因此,对红曲米等补充品的需求减少了。这使得製造商难以采购原料,经销商也难以交付产品,阻碍了整体市场活动。儘管随着人们更加关注预防性医疗保健,市场有望復苏,但疫情的影响可能会持续一段时间。
预计粉末细分市场在预测期内将是最大的
由于易于掺入各种食品和食品和饮料中,粉末行业预计将享受良好的成长,因为它扩展到传统补充品之外的应用领域。这项创新满足了消费者对便利性和可客製化消费的偏好,推动了需求和市场成长。此外,红曲米通常保留其营养价值,并保持其降低胆固醇的特性,从而促进市场成长。
预计营养补充食品在预测期内复合年增长率最高
预计营养补充食品在预测期内将以最高的复合年增长率成长。这是因为它的降低胆固醇作用已被广泛认可,并且是心血管保健补充品中广受欢迎的成分。将红曲米纳入营养补充扩大了消费者的覆盖范围,并提供了一种方便、标准化的方式将红曲米的健康益处融入个人的日常生活。将红曲米与其他心臟健康成分混合的组合补充品的需求进一步增加了红曲米市场的存在。
预计亚太地区将在预测期内占据最大的市场占有率,因为红曲米因其独特的风味和颜色而传统上用于亚洲料理。红曲米因其微妙的甜味而经常被使用,并赋予食品微红色。此外,红曲米因其潜在的健康益处而广受欢迎,尤其是在控制胆固醇水平方面。一些研究表明,红曲米中的莫纳可林 K 可能有助于降低低密度脂蛋白胆固醇水平,从而推动市场成长。
红曲米通常在北美作为营养补充出售和消费,预计它具有特别的降低胆固醇的作用,因此预计北美在预测期内的复合年增长率最高。消费者可以使用红曲米补充品作为传统他汀类药物的天然替代品。此外,北美有多家公司生产和销售红曲米补充品,市场竞争包括产品品质、品牌声誉和行销策略等因素。
According to Stratistics MRC, the Global Red Yeast Rice Market is accounted for $1.1 billion in 2023 and is expected to reach $2.4 billion by 2030 growing at a CAGR of 12.4% during the forecast period. Red Yeast Rice (RYR) is a traditional Chinese culinary and medicinal product made by fermenting rice with the Monascus purpureus mold. It contains naturally occurring compounds known as monacolins, with monacolin K being identical to lovastatin, a cholesterol-lowering medication. RYR has been used for centuries in traditional Chinese medicine to promote cardiovascular health. Its active compounds are believed to inhibit cholesterol synthesis and lower LDL ("bad") cholesterol levels. Some people use RYR as a natural alternative for managing cholesterol levels.
Rising awareness of natural cholesterol-lowering solutions
As consumers become more health-conscious and seek alternatives to synthetic medications, red yeast rice, known for its potential to lower cholesterol levels, has gained popularity. The rising awareness of the adverse effects associated with conventional cholesterol-lowering drugs has driven individuals toward natural remedies. Consumers are actively seeking products like red yeast rice that offer a natural approach to managing cholesterol without compromising overall health. Thus, the demand for red yeast rice has surged as people recognize its historical use in traditional medicine and its alignment with the broader trend of embracing natural, plant-based solutions for health and wellness.
Safety concerns and potential side effects
Safety concerns surrounding red yeast rice cast a shadow over the market. Unlike strictly regulated prescription drugs, red yeast rice can cause muscle aches, digestive issues, and interact with other medications. These potential side effects raise red flags for both consumers and healthcare professionals. Consumers wary of unintended consequences may opt for established medications. Further doctors, prioritizing patient safety, might hesitate to recommend red yeast rice due to the lack of long-term data and potential interactions with current medications.
Growing prevalence of cardiovascular diseases
Cardiovascular health concerns escalate globally; there is an increased demand for natural solutions that can contribute to cholesterol management, a key factor in cardiovascular health. Red yeast rice, containing compounds like monacolins, which may help lower cholesterol levels, has gained attention as a potential preventive measure against heart-related issues. The rise in CVD cases has prompted individuals to seek proactive approaches to manage heart health, driving the adoption of red yeast rice supplements contributing to the market growth.
Competition from established cholesterol-lowering drugs
The dominance of established cholesterol-lowering medications throws a significant hurdle at the red yeast rice market. These prescription drugs boast a long history of proven effectiveness, extensive clinical research, and the trust of doctors. This makes them the go-to option for many healthcare providers, hindering red yeast rice's integration into mainstream cholesterol management. Furthermore, established drugs may be covered by insurance, making them a more cost-effective choice for some patients compared to out-of-pocket expenses for red yeast rice.
Covid-19 Impact
The COVID-19 pandemic impacted the red yeast rice market in two key ways. Firstly, the focus shifted towards immediate health concerns. People prioritized treating and preventing COVID-1chronic health conditions like high cholesterol took a backseat. This led to a decline in demand for supplements like red yeast rice. This made it difficult for manufacturers to source ingredients and distributors to deliver the product, hindering overall market activity. While the market is expected to recover as people resume focusing on preventative healthcare, the pandemic's effects are likely to be felt for some time.
The powder segment is expected to be the largest during the forecast period
The powder segment is estimated to have a lucrative growth, owing to ease of incorporation into various food and beverage products, expanding its usage beyond traditional supplements. This innovation caters to consumer preferences for convenient and customizable consumption, driving demand and market growth. Additionally, powdered Red Yeast Rice often retains its nutritional benefits, maintaining its cholesterol-lowering properties encourage the market growth.
The dietary supplements segment is expected to have the highest CAGR during the forecast period
The dietary supplements segment is anticipated to witness the highest CAGR growth during the forecast period, due to widely recognized for its potential cholesterol-lowering benefits, it has become a sought-after ingredient in cardiovascular health supplements. The incorporation of Red Yeast Rice into dietary supplements has expanded its consumer reach, offering individuals a convenient and standardized way to incorporate its health benefits into their daily routines. The demand for combination supplements, blending Red Yeast Rice with other heart-healthy ingredients, has further amplified its market presence.
Asia Pacific is projected to hold the largest market share during the forecast period because red yeast rice has been traditionally used in Asian cuisines for its distinctive flavor and color. It is often used to impart a reddish hue to food, as well as for its subtle sweet taste. Moreover, red yeast rice has gained popularity for its potential health benefits, particularly in managing cholesterol levels. Some studies suggest that the monacolin K in red yeast rice may help a lower LDL cholesterol level which boosts the market growth.
North America is projected to have the highest CAGR over the forecast period, as red yeast rice is often marketed and consumed in North America as a dietary supplement, particularly for its potential cholesterol-lowering properties. Consumers may use red yeast rice supplements as a natural alternative to traditional statin medications. Additionally, various companies in North America may produce and distribute red yeast rice supplements and competition in the market can involve factors such as product quality, brand reputation, and marketing strategies.
Key players in the market
Some of the key players in the Red Yeast Rice Market include Shanghai Fengyi Biotechnology Co., Ltd, Nutraceuticals International Group, Golden Grain Group Limited, Zhejiang Sanhe Bio-Tech Co., Ltd., Nanjing Zelang Medical Technology Co., Ltd., Wuhan Jiacheng Biotechnology Co., Ltd, Fermentek Biotechnology, Hebei Food Additive Co., Ltd., CSPC Pharmaceutical Group Limited, Alesco S.r.L., Amazing Nutrition, Giellepi SpA, Sylvan Wellness, PLAMED Green Science Group, NOW Health Group, Purelife Bioscience Co Ltd, Natural Plus and Swanson
In January 2024, NOW Sports Named Official Sports Nutrition Partner of the Brooks Beasts Track Club. The strategic alignment comes as Brooks professional athletes look to compete on the world's biggest stage at this summer's 2024 Paris Olympics
In January 2024, NOW Partners with Top Wellness Experts to Launch You're Enough NOW Campaign. Peloton instructor emma lovewell, Celebrity Health Coach Kelly LeVeque, and Functional Medicine Practitioner Dr. Will Cole Will Inspire People to Feel Fulfilled, Nourished and Strong
In July 2023, Plamed launched a speech and participated the exhibition at Ringier PCT 2023. Many big names from domestic and foreign beauty and personal care brands, raw material supplier, OEM companies, scientific research institutes, and industry associations gathered in large numbers.